Patents by Inventor David F. Chen

David F. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240167009
    Abstract: Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).
    Type: Application
    Filed: December 21, 2023
    Publication date: May 23, 2024
    Inventors: Jennifer A. Doudna, David Burstein, Janice S. Chen, Lucas B. Harrington, David Paez-Espino, Jillian F. Banfield
  • Patent number: 11970719
    Abstract: Provided are compositions and methods that include one or more of: (1) a Class 2 CRISPR/Cas effector protein, a nucleic acid encoding the effector protein, and/or a modified host cell comprising the effector protein (and/or a nucleic acid encoding the same); (2) a CRISPR/Cas guide RNA that binds to and provides sequence specificity to the Class 2 CRISPR/Cas effector protein, a nucleic acid encoding the CRISPR/Cas guide RNA, and/or a modified host cell comprising the CRISPR/Cas guide RNA (and/or a nucleic acid encoding the same); and (3) a CRISPR/Cas transactivating noncoding RNA (trancRNA), a nucleic acid encoding the CRISPR/Cas trancRNA, and/or a modified host cell comprising the CRISPR/Cas trancRNA (and/or a nucleic acid encoding the same).
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 30, 2024
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, David Burstein, Janice S. Chen, Lucas B. Harrington, David Paez-Espino, Jillian F. Banfield
  • Publication number: 20240127444
    Abstract: One example method for biomarker detection in digitized pathology samples includes receiving a plurality of image patches corresponding to an image of a pathology slide having a hematoxylin and eosin-stained (“H&E”) stained sample of tissue, each image patch representing a different portion of the image; for each image patch, determining, using a first trained machine learning (“ML”) model, a patch biomarker status; and determining, using a second trained ML model, a tissue sample biomarker status for the sample of tissue based on the patch biomarker statuses of the image patches.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 18, 2024
    Applicant: Verily Life Sciences LLC
    Inventors: Craig Mermel, Po-Hsuan Chen, David F. Steiner, Ronnachai Jaroensri, Paul Gamble, Fraser Tan
  • Publication number: 20090252309
    Abstract: A system that incorporates teachings of the present disclosure may include, for example, a communication device having a controller to transmit to a communication system a PKI certificate, and engage in encrypted communications responsive to receiving a public key from the communication system. The communication system can have a plurality of network elements that integrate operations of a circuit-switched communication network and a packet-switched communication network. Other embodiments are disclosed.
    Type: Application
    Filed: April 2, 2008
    Publication date: October 8, 2009
    Applicant: AT&T KNOWLEDGE VENTURES, L.P.
    Inventors: Loraine Beyer, David F. Chen, Peter Rosencrantz, Tho Tran